Lodoxamide-Loaded Nanofibrous Wound Dressings Promote Wound Healing via Downregulation of IL-1β, NFK-β, and GPx Genes

Diabetic wounds are major clinical challenges which need immediate care to prevent complications such as limb amputation. There are a variety of treatment strategies available for the treatment of diabetic wounds among which wound dressings are the most effective and provide better therapeutic outcome. Lodoxamide was loaded into gelatin scaffolds in order to develop a potential wound dressing material for diabetic wound healing. Electrospinning method was used for the fabrication of wound dressings containing three different concentrations of 1 w/w%, 3 w/w%, and 6 w/w% of Lodoxamide. The developed scaffolds were studied regarding their various physicochemical and biological properties. In vitro study showed that the dressings containing 3% drug had significantly higher cell viability and cytoprotection under oxidative stress. Therefore, this formulation was chosen for treating diabetic wounds in a rat model of excisional diabetic wound. In vivo study showed that gelatin/3% Lodoxamide group had higher wound healing compared with other experimental groups. Gene expression studies showed that the wounds treated with drug-delivering wound dressings showed significantly lower tissue expression level of glutathione peroxidase gene, IL-1 β gene, and NFK- β gene.